Brief Report: Intestinal Lymphangiectasia with Selpercatinib and Pralsetinib Treatment.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
113 patients, 33 (29%) had IL-associated radiologic findings.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Cumulative incidence at 1, 3, and 5 years was 11% (95% CI 6-18%), 27% (95% CI 19%-36%), and 31% (95% CI 22%-41%).
[BACKGROUND] Selective RET inhibitors (SRIs) have durable activity in RET fusion-positive lung cancers.
- p-value p=0.001
- 95% CI 6-18
APA
J RP, S D, et al. (2026). Brief Report: Intestinal Lymphangiectasia with Selpercatinib and Pralsetinib Treatment.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 103704. https://doi.org/10.1016/j.jtho.2026.103704
MLA
J RP, et al.. "Brief Report: Intestinal Lymphangiectasia with Selpercatinib and Pralsetinib Treatment.." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2026, pp. 103704.
PMID
41933582
Abstract
[BACKGROUND] Selective RET inhibitors (SRIs) have durable activity in RET fusion-positive lung cancers. Insidious side-effects may emerge with long-term use. This is the first systematic analysis of intestinal lymphangiectasia (IL), an underrecognized disorder characterized by dilated intestinal lacteals and potential lymph leakage, in this population.
[METHODS] Patients with RET-altered lung cancers treated with selpercatinib or pralsetinib were eligible for this retrospective analysis. IL was classified as possible (radiologic findings), probable (radiologic and clinical findings), and definite (radiologic, clinical and endoscopic/pathologic findings).
[RESULTS] Of 113 patients, 33 (29%) had IL-associated radiologic findings. Cumulative incidence at 1, 3, and 5 years was 11% (95% CI 6-18%), 27% (95% CI 19%-36%), and 31% (95% CI 22%-41%). Prior immune checkpoint inhibitors exposure was associated with IL risk (HR 3.02: 95% CI, 1.53-5.96; p=0.001). Among patients with IL-associated findings, IL was classified as possible, probable, and definite in 25%, 60%, and 15%. Median time from SRI initiation to radiologic findings (involving the ileum and duodenum in 67% and 24% of IL patients, respectively) was 15 months. Radiologic findings were associated with additional clinical findings (e.g., gastrointestinal symptoms, hypoalbuminemia, hypocalcemia, third spacing) in 76% of patients. All patients with evaluable endoscopic biopsies had mild lacteal dilatation. IL improved radiologically and clinically in 64% of patients after SRI dose reduction or discontinuation.
[CONCLUSION] Drug-induced IL occurs with selpercatinib or pralsetinib treatment. The frequency increases with longer drug exposure. Serial monitoring is essential and when necessary, dose modification. Most cases do not lead to treatment discontinuation.
[METHODS] Patients with RET-altered lung cancers treated with selpercatinib or pralsetinib were eligible for this retrospective analysis. IL was classified as possible (radiologic findings), probable (radiologic and clinical findings), and definite (radiologic, clinical and endoscopic/pathologic findings).
[RESULTS] Of 113 patients, 33 (29%) had IL-associated radiologic findings. Cumulative incidence at 1, 3, and 5 years was 11% (95% CI 6-18%), 27% (95% CI 19%-36%), and 31% (95% CI 22%-41%). Prior immune checkpoint inhibitors exposure was associated with IL risk (HR 3.02: 95% CI, 1.53-5.96; p=0.001). Among patients with IL-associated findings, IL was classified as possible, probable, and definite in 25%, 60%, and 15%. Median time from SRI initiation to radiologic findings (involving the ileum and duodenum in 67% and 24% of IL patients, respectively) was 15 months. Radiologic findings were associated with additional clinical findings (e.g., gastrointestinal symptoms, hypoalbuminemia, hypocalcemia, third spacing) in 76% of patients. All patients with evaluable endoscopic biopsies had mild lacteal dilatation. IL improved radiologically and clinically in 64% of patients after SRI dose reduction or discontinuation.
[CONCLUSION] Drug-induced IL occurs with selpercatinib or pralsetinib treatment. The frequency increases with longer drug exposure. Serial monitoring is essential and when necessary, dose modification. Most cases do not lead to treatment discontinuation.